Avalo Therapeutics's market cap is currently ―. The company's EPS TTM is $-381.561; its P/E ratio is -0.04; Avalo Therapeutics is scheduled to report earnings on May 9, 2024, and the estimated EPS forecast is $-1.18. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 236.00K	$ 643.00K	$ 475.00K	$ 896.00K	$ 14.95M
Gross Profit	$ -11.00K	$ -65.00K	$ -76.00K	$ 239.00K	$ 14.42M
EBIT	$ -5.22M	$ -8.19M	$ -9.95M	$ -8.85M	$ 4.09M
EBITDA	$ -4.05M	$ -7.80M	$ -9.56M	$ -8.89M	$ 4.13M
Net Income Common Stockholders	$ -5.23M	$ -8.19M	$ -9.96M	$ -9.82M	$ 3.19M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 10.20M	$ 6.32M	$ 16.76M	$ 13.21M	$ 16.94M
Total Assets	$ 29.27M	$ 24.23M	$ 36.23M	$ 33.40M	$ 36.55M
Total Debt	$ 0.00	$ 14.12M	$ 19.77M	$ 19.42M	$ 19.59M
Net Debt	$ -10.20M	$ 7.80M	$ 3.00M	$ 6.20M	$ 2.65M
Total Liabilities	$ 14.57M	$ 31.20M	$ 42.50M	$ 33.39M	$ 38.58M
Stockholders Equity	$ 14.70M	$ -6.97M	$ -6.27M	$ -10.89M	$ -2.03M
Cash Flow	-
Free Cash Flow	$ -6.80M	$ -10.98M	$ 146.00K	-	$ 5.69M
Operating Cash Flow	$ -6.80M	$ -10.98M	$ 146.00K	-	$ 5.73M
Investing Cash Flow	-	-	$ -133.00K	-	$ -39.00K
Financing Cash Flow	$ 10.70M	$ 598.00K	$ 13.75M	-	$ 0.00

Currency in USD

Avalo Therapeutics Earnings and Revenue History

Income Statement >

Avalo Therapeutics Debt to Assets

Balance Sheet >

Avalo Therapeutics Cash Flow

Cash Flow >

Avalo Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing